


Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.







STEMI IN A COVID-19 PATIENT WITH FACTOR V LEIDEN ON DIRECT-ORAL ANTICOAGULATION THERAPY

Moderated Poster Contributions Complex Clinical Cases Moderated Poster Theater 3_Hall C Saturday, April 2, 2022, 10:45 a.m.-10:55 a.m.

Session Title: CVT Team Work Makes the Dream Work: Exemplary Team-Based Cases! Abstract Category: CVT: Coronavirus Disease (COVID-19) Presentation Number: 1010-11

Authors: Omkar Betageri, Iain Thompson, Adam Hafeez, Mary Shields, Richard Kerensky, University of Florida, Gainesville, FL, USA

Background: Factor V Leiden (FVL) is the most common inherited form of thrombophilia implicated in increasing baseline risk of venous and arterial thromboembolism. In this case, we describe a rare report of COVID 19 associated ST elevation Myocardial Infarction (STEMI) in a patient with a baseline FVL mutation, while on anticoagulation with Direct Oral Anticoagulants (DOAC) therapy.

Case: A 75-year-old male with past medical history of coronary artery disease, FVL complicated by recurrent deep vein thromboses and pulmonary emboli on DOAC (apixaban) therapy presenting for acute hypoxic respiratory failure secondary to COVID 19 infection in the setting of elevated inflammatory markers. Acute ST-elevations on telemetry leads with EKG performed confirming acute anterolateral ST-elevation myocardial infarction. Emergent coronary angiography demonstrated total occlusion of middle left anterior descending (LAD) artery. Subsequent thrombectomy revealed large intra luminal thrombus. A total of 3 stents were place to the mid-distal LAD.

Decision-making: We report a rare case of a thrombotic STEMI in a patient with acute COVID-19 infection, elevated inflammatory markers, and preexisting FVL mutation on DOAC therapy. In patients with COVID-19 and underlying factors contributing to hypercoagulability, providers should have a high suspicion for thrombotic states and a low threshold for cardiac catheterization as early thrombectomy and initiation of anticoagulation may reduce risk of mortality.

Conclusion: Providers should consider prompt and aggressive anticoagulation strategies coupled with a low threshold to pursue diagnostic testing in patients with COVID-19 and pre-existing hypercoagulability disorders. Multidisciplinary patient care involving hematology is specifically indicated in these circumstances.